Skip to main content
TETRATHERIX LIMITED logo

TETRATHERIX LIMITED — Investor Relations & Filings

Ticker · TTX ISIN · AU0000400574 ASX Manufacturing
Filings indexed 68 across all filing types
Latest filing 2026-05-27 Share Issue/Capital Cha…
Country AU Australia
Listing ASX TTX

About TETRATHERIX LIMITED

https://tetratherix.com/

Tetratherix Limited is a regenerative medicine company focused on the development of advanced synthetic scaffolds for bone and tissue repair. The company utilizes proprietary polymer technology to create biocompatible, resorbable materials that mimic the natural extracellular matrix, providing a structural framework for cellular attachment and tissue regeneration. Its primary product line includes synthetic bone graft substitutes designed for use in orthopedic, dental, and maxillofacial surgical procedures. These scaffolds are engineered with high porosity to facilitate vascularization and are gradually replaced by natural bone during the healing process. Tetratherix aims to provide clinical solutions that enhance the body's innate ability to repair complex bone voids and soft tissue defects through innovative material science.

Recent filings

Filing Released Lang Actions
Proposed issue of securities - TTX 9 pages 27.8KB
Share Issue/Capital Change Classification · 96% confidence The document is an ASX Appendix 3B announcing a proposed issue of securities under a share purchase plan and placement. It details classes, numbers, pricing, timetables, and ASX Listing Rule compliance for new share issues, fitting the "Share Issue/Capital Change" category.
2026-05-27 English
Successful Completion $15M Placement 49 pages 10.7MB
Capital/Financing Update Classification · 93% confidence The document is an ASX release announcing a $15M placement and a capped $2M share purchase plan to existing shareholders, including detailed issue pricing, settlement dates, SPP terms and record dates. This is a financing activity announcement (capital raising) of new share issuance. Although an investor presentation is attached, the primary purpose is to update on the Placement and SPP financing. This matches the Capital/Financing Update (CAP) category.
2026-05-27 English
Trading Halt 2 pages 311.9KB
Regulatory Filings Classification · 85% confidence The document is an ASX market announcement notifying a trading halt at the company’s request under ASX Listing Rule 17.1, pending a material capital raising announcement. It does not present financial statements, investor presentation materials, nor detailed financing terms—rather, it is a regulatory announcement of a trading halt. Thus it falls under General Regulatory Filings (RNS).
2026-05-25 English
Quarterly Activities/Appendix 4C Cash Flow Report 16 pages 8.8MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Q3 FY26 QUARTERLY ACTIVITIES REPORT' and is an ASX announcement dated April 23, 2026. It contains detailed business highlights, clinical trial updates, commercial agreements, manufacturing updates, and financial commentary including cash flow and payments to related parties. The content covers a specific quarter (Q3 FY26) and includes substantive financial data and operational analysis. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements or substantive financial data and analysis. The document is not merely an announcement of a report but the report itself, and it is not a short summary or a certification. Therefore, the correct classification is IR with high confidence. Q3 2026
2026-04-22 English
Notification regarding unquoted securities - TTX 6 pages 18.8KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted securities under an employee incentive scheme by Tetratherix Limited. It includes specifics such as security codes, issue dates, and quantities issued. The content focuses on the notification of new securities issued, which aligns with announcements related to share issues or capital changes. There is no indication of financial statements, management discussion, or regulatory certifications. The document is a formal announcement of a share issue event, not a full report or financial statement. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail support a high confidence in this classification.
2026-03-31 English
Tetratherix March Investor Presentation 35 pages 10.3MB
Investor Presentation Classification · 95% confidence The document is titled 'Tetratherix Investor Presentation March 2026' and contains detailed descriptions of the company's technology platform, market opportunities, commercial model, R&D investments, and strategic positioning. It is structured as a presentation with multiple sections explaining the product, market trends, and business model. There are no financial statements, regulatory filings, or voting results. The content is typical of an investor presentation aimed at providing investors with an overview of the company's technology, strategy, and market potential. Therefore, the document fits the category of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2026-03-16 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.